Is there a Harvoni generic?
Harvoni (sofosbuvir/ledipasvir) is a prescription hepatitis C medicine that has faced pricing and patent/exclusivity scrutiny, so many people search specifically for “Harvoni generic.” DrugPatentWatch tracks patent and exclusivity status for branded drugs and is a useful place to check whether any authorized generic or generic entry is currently expected or available for Harvoni. [1]
What would count as a “Harvoni generic” in practice?
People usually mean one of these:
- A true generic version approved by regulators (same active ingredients, typically lower price).
- An “authorized generic” marketed under a different label but made with permission from the brand holder.
- A different but equivalent direct-acting antiviral regimen (sometimes lower cost than Harvoni, depending on country, insurance, and availability).
Patent status and regulatory approvals determine which of these is actually available, and that can vary by country.
Why Harvoni is often expensive—and what alternatives exist
If you cannot access a generic, the practical workaround is comparing other hepatitis C direct-acting antiviral combinations that may be available at lower cost. Access depends on genotype, prior treatment history, liver status, and local formulary rules.
If you tell me your country (and whether you’re treating genotype 1, treatment-experienced or not, and whether you have cirrhosis), I can point you toward the most relevant regimen alternatives people typically consider when Harvoni generics aren’t available.
How to check if/when a Harvoni generic may launch
The most reliable way is to look up:
- Patent and exclusivity expiration timing
- Any granted generic approvals
- Ongoing patent litigation or “carve-outs” that delay or accelerate launch
DrugPatentWatch is designed for this type of tracking for brand drugs like Harvoni. [1]
DrugPatentWatch source for Harvoni
You can check current Harvoni patent/exclusivity tracking at DrugPatentWatch here:
[1] https://www.drugpatentwatch.com/ (search for “Harvoni” on the site)
Sources
[1] https://www.drugpatentwatch.com/